Abstract: In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.

Abstract: In accordance with the present invention, disclosed is a method of conferring, upon a host cell, resistance to retroviral infection by interfering with one or more of the infection processes including retroviral replication and assembly into infective viral particles. The method involves introducing a vector into a host cell, wherein the vector comprises a polynucleotide which directs transcription, within the host cell, of RNA which is a) complementary or homologous, depending on the target region, to a nucleic acid sequence within one or more regions of the genome of the retrovirus; and b) is effective in inhibiting retroviral replication and/or interfering with assembly into viral particles when the host cell is infected. Also disclosed is a method of treatment using cells upon which resistance to infection has been conferred.

Abstract: A thermostable premix for use in animal feeds which comprises a carrier material onto which an enzyme solution containing enzymes which are not inherently heat stable are absorbed.

Abstract: Disclosed is a method of producing fusion proteins, particularly HCV fusion proteins, wherein one part of the fusion protein is formed from the bacterial protein CKS.

Abstract: The present invention provides a fail-safe combination of chemical and physical means for rendering a blood product which comprises a labile blood protein free of viruses without incurring protein denaturation. The blood product is contacted with an effective amount of a selected chemical disinfectant, preferably, sodium thiocyanate in combination with a physical process, preferably, ultrafiltration. The blood product may be plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant containing viruses such as hepatitis or human immunodeficiency virus.

Abstract: This invention relates to deliberately increasing growth hormone in swine during the last 2 weeks of pregnancy through a 3 week lactation. This has the effect of increasing fetal energy storage during late pregnancy which resulted in the newborn piglets having marked enhancement of the ability to maintain plasma concentrations of glucose and free fatty acids when fasted after birth. Likewise, treatment of the sow during lactation results in increased milkfat in the colostrum and an increased milk yield. These effects are important in enhancing survivability of newborn pigs and weight gain prior to weaning.

Abstract: Thrombolytic hybrids are formed as covalent or non-covalent complexes of fibrin fragments and plasminogen activator molecules. Native plasmin degradation fragments of fibrin or non-native fibrin fragments are covalently or non-covalently linked to plasminogen activators such as t-PA, scu-PA, urokinase, streptokinase, and the like. Useful native fibrin fragments which may be utilized to form complexes with plasminogen activators include fragments E.sub.1, E.sub.2, E.sub.3, D and DD, and (DD)E complex. The fibrin fragment component targets the hybrid to vascular thrombi, immobilizing the plasminogen activator molecule onto the fibrin surface of the thrombus. Once localized on a thrombus surface, the plasminogen activator component of the hybrid activates only the clot-surface bound plasminogen transported by the fibrin fragment vehicle, without significant systemic activation of plasminogen.

Abstract: The present invention is directed to a method for the treatment of Parkinson's disease which affect the dopaminergic system by implanting into the brain of a host in need thereof an anti-neurodegenerative effective amount of activated leukocytes.

Abstract: Nucleic acid sequences are disclosed that encode carcinoembryonic antigens (CEAs) as are replicable recombinant cloning vehicles containing DNA that encodes CEA proteins.

Abstract: A method for the treatment of bone lesions or bone deficiencies in a living mammal comprising administering a composition comprising an inorganic phase and an organic phase wherein the inorganic phase comprises a porous particulate TCP ceramic or a nonporous or microporous particulate HAP ceramic or a mixture of porous particulate TCP ceramic and nonporous or microporous particulate HAP ceramic, wherein the organic phase comprises a purified hydrated collagen product which is mixed with and forms a continuous or substantially continuous surface coating over said inorganic phase(s) and a hydrated collagen-demineralized bone product which is mixed with and forms a substantially continuous surface coating over said purified hydrated collagen product surface coating or the organic phase comprises a hydrated collagen-demineralized bone product which is mixed with and forms a continuous or substantially continuous surface coating over said inorganic phase and a purified hydrated collagen product which is mixed with

Abstract: A method and therapeutic composition for the treatment of pathological disorders associated with endogenous peptides by the administration of enkephalinase or derivatives thereof.

Abstract: The present invention comprises a method for impeding the formation of tumor metastasis or tumor invasiveness in a host. Such inhibition comprises administration to the host of a glycosaminoglycan derivative substantially devoid of anticoagulation activity and is an effective inhibitory of heparanase activity. Such a glycosaminoglycan derivative may be provided by purchase or synthesis as directed herein. Parenteral administration to a tumor-bearing host of the glycosaminoglycan derivative results in the exposure of host-borne tumor cells thereto. Such exposure to effective levels of the derivative results in the inhibition of tumor heparanase activity and a lessening of invasiveness and metastatic spread.Heparin, a glycosaminoglycan particularly effective as a heparanase inhibitor and an anti-clotting agent, is a preferred glycosaminoglycan for derivatization.

Abstract: An antithrombin solution for preventing fibrin formations, including antithrombin at a concentration of more than 0.5 U/ml and not more than 250 U/ml, a physiological buffer and optionally sodium hyaluronate. A related surgical method includes applying the solution directly during surgery to exposed tissue. The solution can also be injected into the synovial cavity of patients with active arthritis as therapeutic orthopaedics.

Abstract: An acid inhibitor of bacterial origin which is effective in inhibiting acid secretion from gastric parietal cells; a method of producing this acid inhibitor; a method of administering the acid inhibitor to reduce acid secretion by parietal cells; and a therapeutic composition, which includes the acid inhibitor, for use in the method. In particular, the invention relates to a protein produced by gastric Spirilla, such as Helicobacter pylori (H. pylori), which is effective in inhibiting acid secretion by parietal cells and, thus, can be used in the treatment of peptic ulcer disease and other conditions of the gastroduodenal tract in which there is a tendency for ulceration.

Abstract: A method and apparatus for reducing the levels of low density lipoproteins (LDL) in blood is disclosed. The LDL is contacted with an enzyme which modifies it in a manner such that the LDL is rapidly removed endogenously by the patients' own metabolic processes. The enzyme may be introduced into the patient by injection, transdermal transport, nasal insufflation and ingestion. Additionally, the enzyme may be contained in a reactor for both in vivo and extracorporeal use.

Abstract: There is disclosed an immunotherapy method for treating an individual with cancer or a viral infection comprising obtaining lymphoid cells previously exposed to a specific antigen, culturing the lymphoid cells ex vivo in a culture medium containing an effective amount of an IL-7 polypeptide or a functional derivative thereof to induce CTL activity in the lymphoid cells and administering the lymphoid cells having CTL activity for cells displaying the specific antigen to an individual.

Abstract: A transacting DNA binding factor is disclosed. The ASF 1 protein factor specifically binds to the sequence motif TGACG found upstream of the promoter in many plant genes. Coexpression of this protein factor augments the level of expression of the up-regulated promoter containing the TGACG motif.

Abstract: A pharmaceutical composition for the treatment of hoarseness. The composition is administered orally in unit dosage form. It is based on the combination of Varidase (a combination of streptokinase and streptodornase), an antiinflammatory corticosteroid, an antihistamine and an expectorant. The composition may optionally contain vitamins, like vitamin B.sub.1 or Vitamin B.sub.2. The invention further relates to a method for the treatment of hoarseness in humans, which comprises administering an effective quantity of a composition as defined above.

Abstract: A method for scavenging free iron or aluminum in fluids such as physiological fluids involves a provision in such fluids of a soluble polymer substrate having chelator immobilized thereon. According to the invention preferred such compounds comprise polysaccharides or proteins having a deferoxamine moiety thereon. Such a compound can be used for the treatment of iron overload, as well as to inhibit cell damage from oxidation/reduction reactions. In one embodiment, cell damage during reperfusion is inhibited, through provision of the chelating moiety at the site of reperfusion.